Page 105 - 《中国药房》2024年9期
P. 105

3种第三代四环素类抗菌药物ADE信号的挖掘与分析
                                                                                            Δ


                                        #
                *
          梁碧怡 ,杨惠霞,黄小梅,任剑雄(佛山市中医院临床药学室,广东 佛山 528000)
          中图分类号  R978.1+4      文献标志码  A      文章编号  1001-0408(2024)09-1123-06
          DOI  10.6039/j.issn.1001-0408.2024.09.17

          摘  要  目的  基于美国FDA不良事件报告系统(FAERS)数据库,挖掘3种第三代四环素类抗菌药物(替加环素、奥马环素、依拉
          环素)的药物不良事件(ADE)信号,为临床安全使用该类药物提供依据。方法  检索美国FAERS数据库中2005年第1季度至2023
          年第2季度替加环素、奥马环素、依拉环素的ADE报告,采用报告比值比法和比例报告比值法对3种药物的ADE信号进行挖掘,并
          进行分析。结果  共获得以替加环素、奥马环素、依拉环素为首要怀疑药物的ADE报告2 538份,其中替加环素2 135份、奥马环素
          349份、依拉环素54份。替加环素的ADE阳性信号有131个,共涉及19个系统器官分类(SOC),主要集中在各类检查、肝胆系统
          疾病、血液及淋巴系统疾病、胃肠系统疾病等;信号较强的首选术语(PT)分别是低纤维蛋白原血症和血纤维蛋白原降低等;肾衰、
          急性肾损伤、出血等14种ADE在其说明书中未提及。奥马环素的ADE阳性信号有24个,共涉及6个SOC,主要集中在胃肠系统
          疾病、各类检查等;信号较强的 PT 分别是牙齿变色、喷射样呕吐、粪便松软等;其说明书未提及的 ADE 有唇部肿胀、胃食管反流
          病、嗜酸粒细胞增多症、皮肤变色、粪便松软、盗汗。依拉环素的ADE阳性信号有5个,共涉及4个SOC,主要集中在各类检查、胃
          肠系统疾病等;信号较强的PT分别是血纤维蛋白原降低和低纤维蛋白原血症。结论  3种第三代四环素类药物涉及胃肠系统的
          ADE最多,使用时尤其要注意替加环素所致胰腺炎类疾病和奥马环素口服所致胃食管反流病的ADE。在用药期间应定期监测患
          者肝功能、肾功能(使用替加环素时)、凝血功能(使用替加环素、依拉环素时),以防范严重ADE的发生。
          关键词  替加环素;奥马环素;依拉环素;药物不良事件;信号挖掘;胰腺炎;胃食管反流病;FAERS数据库


          Data mining and analysis for ADE signals of three third-generation tetracycline antibiotics
          LIANG Biyi,YANG Huixia,HUANG Xiaomei,REN Jianxiong(Clinical  Pharmacy  Room,  Foshan  Hospital  of
          Traditional Chinese Medicine, Guangdong Foshan 528000, China)

          ABSTRACT   OBJECTIVE  To  excavate  the  adverse  drug  event (ADE)  signals  of  three  third-generation  tetracycline  antibiotics
         (tigecycline,  omadacycline,  eravacycline)  based  on  FDA  adverse  event  reporting  system (FAERS),  and  to  provide  reference  for
          the safe use of them. METHODS The ADE reports of tigecycline, omadacycline and eravacycline from the first quarter of 2005 to
          the second quarter of 2023 were retrieved from FAERS database. The ADE signals of 3 kinds of drugs were mined by the method
          of reporting odds ratio method and the proportional reporting ratio method. RESULTS Totally 2 538 ADE reports with tigecycline,
          omadacycline  and  eravacycline  as  the  primary  suspected  drugs  were  obtained,  including  2  135  tigecycline  ADE  reports,  349
          omadacycline  ADE  reports  and  54  eravacycline  ADE  reports.  A  total  of  131  ADE  positive  signals  of  tigecycline  were  mined,
          involving  19  system  organ  classes (SOCs),  mainly  concentrated  in  investigations,  hepatobiliary  system,  blood  and  lymphatic
          system, and gastrointestinal system, etc; the preferred terminologies (PT) with intense signal were hypofibrinogenaemia and blood
          fibrinogen  decreased.  Fourteen ADE  signals  were  not  mentioned  in  the  drug  instruction,  such  as  renal  failure,  acute  kidney  injury
          and  hemorrhage.  Totally  24  ADE  positive  signals  of  omadacycline  were  mined,  involving  6  SOCs,  mainly  concentrated  in  the
          gastrointestinal system and various examinations; the PTs with intense signals were tooth discoloration, jet-like vomiting and loose
          feces,  etc.  ADE  signals  were  not  mentioned  in  the  drug  instructions,  included  lip  swelling,  gastroesophageal  reflux  disease,
          eosinophilia,  skin  discoloration,  feces  softening,  and  night  sweats.  Five  ADE  positive  signals  of  eravacycline  were  mined,
          involving  4  SOCs,  mainly  concentrated  in  various  examinations,  gastrointestinal  system,  etc. The  most  intense ADE  signals  were
          blood  fibrinogen decreased and  hypofibrinogenaemia.  CONCLUSIONS  ADE  of  the  gastrointestinal  system  are  mostly  identified in
          the  three  third-generation  tetracycline  antibiotics,  especially  pancreatitis  caused  by  tigecycline  and  gastroesophageal  reflux  disease
                                                             caused  by  oral  administration  of  omadacycline.  The  liver
             Δ 基金项目 佛山市科技局科技创新项目(No.2220001005371)           function,  renal  function  (for  tigecycline)  and  coagulation
             *第一作者 副主任药师,硕士。研究方向:抗感染药物。E-mail:
                                                             function (for  tigecycline,  eravacycline)  should  be  monitored
          biyiliang@hotmail.com
             # 通信作者 主任中药师。研究方向:中药临床药学、药事管理。                  regularly during medication, so as to prevent the occurrence of
          电话:0757-83068120。E-mail:1727313578@qq.com          serious ADE.


          中国药房  2024年第35卷第9期                                                China Pharmacy  2024 Vol. 35  No. 9    · 1123 ·
   100   101   102   103   104   105   106   107   108   109   110